60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
February 20, 2024 07:59 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals will Sponsor Pre-Clinical Studies ofTafenoquine Use in Candida spp, Including Candida auris
7 Hills Logo.png
7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
May 22, 2023 13:05 ET | 7 Hills Pharma
HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention &...
ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting
April 06, 2023 08:30 ET | ContraFect Corporation
Oral Presentation of New Data Demonstrating the Activity of Lysin CF-370 Against XDR Pseudomonas aeruginosa New Data Elucidating the Mechanism of Action of CF-370 YONKERS, N.Y., April 06, 2023 ...
ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement
December 13, 2022 08:01 ET | ContraFect Corporation
YONKERS, N.Y., Dec. 13, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections
November 28, 2022 08:00 ET | ContraFect Corporation
YONKERS, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Logo V rgb original.jpg
BlossomHill Therapeutics Closes $71M Series A Financing
March 03, 2021 16:01 ET | BlossomHill Therapeutics, Inc.
SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a biopharmaceutical company focusing on oncology and autoimmune disorders, announced today that the company raised $71...
InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis
June 02, 2020 08:00 ET | InveniAI
GUILDFORD, Conn., June 02, 2020 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across...
Iterum Logo.jpg
Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
March 12, 2020 06:45 ET | Iterum Therapeutics plc
 --Topline data from cUTI and uUTI pivotal trials on track to report around the end of Q1----NDAs anticipated to file with the FDA in mid-2020-- DUBLIN, Ireland and CHICAGO, March 12, 2020 ...
Dan Hassett, PhD, in his laboratory at the University of Cincinnati
Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria
February 21, 2020 08:00 ET | Arch Biopartners
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9328b8b7-9f45-4361-915c-3a569b3716a0 TORONTO, Feb. 21, 2020 (GLOBE NEWSWIRE) --  Arch...
Sinuwave Technologies Receives 2019 President’s Choice Award at the 17th World Congress of the International Photodynamic Association
July 11, 2019 16:40 ET | International Photodynamic Association
Boston, USA, July 11, 2019 (GLOBE NEWSWIRE) -- At the 17th International Photodynamic Association World Congress in Boston, Massachusetts, Sinuwave Technologies Corporation, a subsidiary of Ondine...